A dramatic shift has occurred in the high-profile cases surrounding the controversial COVID-19 supply procurement. The Sandiganbayan, the Philippines’ anti-graft court, has authorized the withdrawal of graft charges against former Budget Undersecretary Lloyd Christopher Lao and key figures from Pharmally Pharmaceutical Corp., a decision that reverberates through the halls of power.
The move stems from a request by the current Ombudsman, Jesus Crispin Remulla, to revisit the charges initially filed under his predecessor, Samuel Martires. Remulla argued for a thorough reassessment of the evidence, seeking to ensure the integrity of the prosecution before proceeding to trial.
The court’s eight-page resolution, dated November 17th, firmly upholds the Ombudsman’s authority. It acknowledges the right of a sitting Ombudsman to revise the decisions of previous administrations, operating within the framework of the law. This decision effectively reverses the course set by Martires’ earlier actions.
At the heart of the controversy lies the awarding of over P8 billion (approximately $143 million USD) in contracts to Pharmally in 2020. The company, with a remarkably small paid-up capital of just P625,000, secured these massive deals for essential medical supplies – PPE, masks, face shields, and crucial PCR test kits.
Senate hearings had previously exposed troubling questions about these transactions. Allegations of significant overpricing and preferential treatment surfaced, with particular scrutiny focused on the role of Michael Yang, a former presidential advisor, and his alleged influence over the procurement process.
Ombudsman Remulla’s decision to seek withdrawal wasn’t based on a lack of evidence, but rather a desire for a more rigorous investigation. He aimed to meticulously re-examine the case, ensuring the charges were undeniably solid before committing to a lengthy and complex trial.
The Sandiganbayan recognized this distinction, acknowledging the Ombudsman’s discretion in establishing probable cause, while also asserting its own authority once formal charges are filed. However, the court ultimately agreed that a deeper scrutiny was warranted.
Concerns were raised by the accused regarding potential delays and violations of their right to a speedy trial. The court addressed these arguments directly, concluding that the benefits of a thorough reassessment outweighed the risk of postponement.
Ultimately, the Sandiganbayan deemed the withdrawal appropriate, stating it saw “no inconsistency” between the initial finding of probable cause for arrest warrants and the decision to allow the charges to be dropped for further investigation. The case now enters a new phase, poised for a potentially transformative reinvestigation.
